stockrowBio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
Follow BIO.B
Alert me
Bio-Rad Laboratories, Inc. (BIO.B) Return on invested capital
Bio-Rad Laboratories, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −0.44%, down 0.8 percentage points from fiscal 2025 (0.41%). Over the past ten years it has ranged from −1.79% (fiscal 2018) to 4.88% (fiscal 2015); the current reading is higher than 18% of that period. That is above the Medical Devices industry median of −5.27% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.41% | (2.34) |
| FY2024 | 2.75% | 0.21 |
| FY2023 | 2.54% | (0.80) |
| FY2022 | 3.34% | 0.90 |
| FY2021 | 2.44% | (0.52) |
| FY2020 | 2.96% | 0.13 |
| FY2019 | 2.83% | 4.62 |
| FY2018 | −1.79% | (4.65) |
| FY2017 | 2.86% | 1.25 |
| FY2016 | 1.61% | (3.27) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PODD Insulet Corporation compare | 18.8% |
| PEN Penumbra, Inc. compare | 12.7% |
| GMED Globus Medical, Inc. compare | 8.86% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BIO.B Bio-Rad Laboratories, Inc. | −0.44% |
| BIO Bio-Rad Laboratories, Inc. compare | −0.44% |
| BRKR Bruker Corporation compare | −1.12% |
| TXG 10x Genomics compare | −20.2% |
| GKOS Glaukos Corporation compare | −24.6% |
| Medical Devices industry median | −5.27% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on BIO.B
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement